Preventive Use of GLP-1 Receptor Agonists: For prediabetes populations with a BMI ≥27 kg/m2, low-dose semaglutide (0.5 mg/week) combined with lifestyle intervention can reduce the risk of developing hypertension by 62% (76). The gene discussed is GLP1R; the disease is Hypertension.